Results 11 to 20 of about 58,972 (283)

Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis

GMS Ophthalmology Cases, 2023
Objective: To present a case with infliximab-induced retrobulbar optic neuritis.Case description: A 58-year-old woman presented to our clinic with a two-day history of blurred vision in her right eye.
Dündar, Sema, Yaşar, Mimbay, Çakmak, Harun, Kıylıoğlu, Nefati, Ünsal, Alparslan   +4 more
doaj   +2 more sources

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

BMC Musculoskeletal Disorders, 2012
Background To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study Methods In a ...
van der Maas Aatke, van den Bemt Bart JF, Wolbink Gertjan, van den Hoogen Frank HJ, van Riel Piet LCM, den Broeder Alfons A   +5 more
doaj   +2 more sources

Infliximab in the treatment of rheumatoid arthritis

Biologics: Targets & Therapy, 2009
A PerdrigerService de Rhumatologie, CHU de Rennes, Hôpital sud, FranceAbstract: Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA).
A Perdriger
doaj   +2 more sources

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure

Gut and Liver
Background/Aims: Studies on elective switching to the subcutaneous (SC) formulation of infliximab revealed comparable efficacy and safety and higher infliximab level than those exhibited by intravenous (IV) infliximab.
June Hwa Bae, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sung Wook Hwang   +10 more
doaj   +2 more sources

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

Clinical and Experimental Gastroenterology, 2009
Garrett Lawlor, Alan C MossBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USAAbstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has become an established therapy for Crohn’s ...
Garrett Lawlor, Alan C Moss
doaj   +1 more source

Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product

Open Access Rheumatology: Research and Reviews, 2017
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ   +8 more
doaj   +1 more source

Safety aspects of infliximab in inflammatory bowel disease patients - A retrospective cohort study in 100 patients of a German University Hospital [PDF]

, 2004
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD).
Seiderer, J., Burkhard Göke, Göke, B., Ochsenkühn, Thomas, Thomas Ochsenkühn, Julia Seiderer   +5 more
core   +1 more source

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

مجلة كلية الطب, 2015
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi, Muhammed M. Al-Ani, Nizar A. Jassim   +2 more
doaj   +1 more source

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.

PLoS ONE, 2015
ObjectiveIn patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg).
Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi, Tiziana Del Bianco   +4 more
doaj   +1 more source

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

BMJ Open Gastroenterology, 2021
Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein, Andres J Yarur, Shaina Sekhri, Bharat Rao, Akanksha Mohananey, Poonam Beniwal-Patel, Alexandra Bruss   +6 more
doaj   +1 more source